首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop
【24h】

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop

机译:骨髓增生异常综合症(MDS)患者的诊断和预后评估方面的最新进展:共识声明和专家研讨会的报告

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Several new treatments for myelodysplastic syndromes (MDS) have recently become available, or are in development. Patients who could benefit from active treatment must be effectively identified and followed up. Therefore, guidelines for the diagnosis and prognostic evaluation of MDS need to be kept up to date with technological and scientific advances. An expert workshop was convened to review currently available and emerging diagnostic technologies and developments in prognostic classification systems, to ensure appropriate management of individual patients. The panel also provided suggestions to ensure adherence to guidelines and highlighted the mandatory requirement for cytogenetic evaluation in patients with MDS.
机译:骨髓增生异常综合症(MDS)的几种新疗法最近已经可用或正在开发中。可以从积极治疗中受益的患者必须得到有效识别和随访。因此,MDS的诊断和预后评估指南必须与技术和科学进步保持同步。召集了一个专家研讨会,以审查预后分类系统中当前可用的和新兴的诊断技术和发展,以确保对个体患者进行适当的管理。该小组还提出了确保遵守指南的建议,并强调了MDS患者进行细胞遗传学评估的强制性要求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号